<DOC>
	<DOC>NCT00529178</DOC>
	<brief_summary>To determine in hypercholesterolemic subjects with chronic, well-compensated liver disease, the percent change from baseline to Week 12 in serum LDL-C of pravastatin 80 mg compared to placebo.</brief_summary>
	<brief_title>Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Chronic, wellcompensated stable liver Hypercholesterolemia Signs or symptoms of ascites, jaundice, or cirrhosis with a ChildPugh Score &gt; 5 History of disorders affecting serum bilirubin levels, more than 1 chronic liver disease, significant endocrine, renal, or gastrointestinal disease, or uncontrolled hypertension Treatment with lipidlowering drugs, unless they have been withdrawn within the timeframe specified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>